ArticleInternational journal of bipolar disorders2026
Baseline NMR lipoprotein profiles in lithium-naïve bipolar disorder patients who later showed weight gain during lithium therapy: a pilot study.
Article in International journal of bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundLithium is a first-line treatment for bipolar disorder (BD), but weight gain is a common side effect, leading to physical comorbidities and reduced average life expectancy. Some individuals are predisposed to weight gain due to lithium therapy, indicating the need to explore metabolic differences to prevent health complications. This descriptive feasibility study aimed to explore metabolic parameters in lithium-naïve BD individuals who later gained weight during lithium therapy versus those who did not.
methodsData from BD individuals (N = 10) were included, five of whom gained weight (≥ 5 kg) during lithium treatment and five who did not. Nuclear Magnetic Resonance spectroscopy was used to measure blood serum lipoprotein and inflammation parameters, as well as molecular metabolites before lithium treatment. Univariate t-tests and multivariate orthogonal partial least-squares discriminant analysis (oPLS-DA) were performed to observe metabolomic between-group differences.
resultsThe multivariate oPLS-DA did not show significant differences between the groups, but data visualization suggested distinct metabolic profiles. Univariate analyses revealed significantly elevated lipoprotein parameters in the weight gain group, which did not remain significant after correction for multiple testing. Phenylalanine levels showed an observable but non-significant downward trend in the weight gain group (fold change = 0.40, p = .057).
conclusionsThe findings suggest a link between weight gain during lithium therapy and altered lipoprotein metabolism, aligning with previous research. However, larger studies are needed to further explore the underlying mechanisms. These preliminary findings represent a stepping stone for personalized lithium treatment strategies, which could help mitigate adverse metabolic side effects and improve treatment adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.